Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Novel insights into mesothelioma biology and implications for therapy.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-07
ICR Author
Yap, Timothy
Popat, Sanjay
Marsden,
Author
Yap, TA
Aerts, JG
Popat, S
Fennell, DA
Type
Journal Article
Metadata
Show full item record
Abstract
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.
URI
https://repository.icr.ac.uk/handle/internal/1195
DOI
https://doi.org/10.1038/nrc.2017.42
Collections
  • Cancer Therapeutics
  • Clinical Studies
Subject
Animals
Humans
Mesothelioma
Neovascularization, Pathologic
Ubiquitin Thiolesterase
Tumor Suppressor Proteins
Antineoplastic Agents
Antibodies, Monoclonal
Immunotherapy
Genes, Tumor Suppressor
Genes, Neurofibromatosis 2
Genes, p16
Proto-Oncogene Proteins c-akt
Protein-Arginine N-Methyltransferases
TOR Serine-Threonine Kinases
GPI-Linked Proteins
Tumor Microenvironment
Phosphoinositide-3 Kinase Inhibitors
Research team
Medicine Drug Development Unit (de Bono)
Thoracic Oncology
Language
eng
License start date
2017-07
Citation
Nature reviews. Cancer, 2017, 17 (8), pp. 475 - 488

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.